Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international ...
Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC ...
Imdelltra demonstrated superior overall survival and progression-free survival compared to standard chemotherapy in ES-SCLC patients post-platinum-based treatment. The DeLLphi-304 trial showed a ...
The FLAURA2 trial showed that combining Tagrisso with chemotherapy improved survival in EGFR-mutated NSCLC, especially in patients with liver metastases and TP53 alterations. Addressing emotional and ...
Medically reviewed by Doru Paul, MD Key Takeaways Survival rates for stage 3 lung cancer can vary between 13% to 36% depending on the subtype.Stage 3a lung cancer is often treated with surgery and ...
Please provide your email address to receive an email when new articles are posted on . Non-lung secondary cancers can develop in survivors of lung cancer years after completion of definitive therapy.